pyrazines has been researched along with olaparib in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Byers, LA; Cristea, S; Fan, YH; Gibbons, DL; Glisson, BS; Heymach, JV; Li, L; Minna, JD; Piwnica-Worms, H; Redwood, AB; Sage, J; Sen, T; Shames, DS; Stewart, CA; Tong, P; Valliani, A; Wang, J | 1 |
| D'Andrea, AD; Do, KT; Dunn, CE; Färkkilä, A; Kirschmeier, PT; Kochupurakkal, BS; Konstantinopoulos, PA; Lazaro, JB; Liu, JF; Matulonis, UA; Palakurthi, S; Parmar, K; Reavis, HD; Reznichenko, E; Sambel, LA; Shapiro, GI; Wang, ZC; Yang, C; Zou, L | 1 |
| Arthur, G; Bebb, DG; Bolyos, A; Bose, P; Goutam, S; Jette, NR; Lees-Miller, SP; Petersen, LF; Radhamani, S; Ye, R | 1 |
| Awasthi, S; Gmeiner, WH; Jonnalagadda, S; Lingareddy, J; Mani, C; Palle, K | 1 |
| D'Andrea, AD; de Jonge, A; Do, KT; Gannon, C; Hedglin, J; Kelland, S; Kochupurakkal, B; Lazaro, JB; Parmar, K; Powers, A; Quinn, N; Shapiro, GI; Vuong, L | 1 |
1 trial(s) available for pyrazines and olaparib
| Article | Year |
|---|---|
Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors.
Topics: Adult; Aged; Aged, 80 and over; Cystadenocarcinoma, Serous; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasms; Ovarian Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Pyrazines; Pyrazoles | 2021 |
4 other study(ies) available for pyrazines and olaparib
| Article | Year |
|---|---|
CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Checkpoint Kinase 1; Cisplatin; Drug Synergism; Female; Gene Knockdown Techniques; Humans; Lung Neoplasms; Mice; Mice, Nude; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Pyrazines; Pyrazoles; Small Cell Lung Carcinoma | 2017 |
The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition.
Topics: Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Cell Line, Tumor; Checkpoint Kinase 1; Cystadenocarcinoma, Serous; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Neoplasm Grading; Ovarian Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Recombinational DNA Repair; Xenograft Model Antitumor Assays | 2019 |
Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Clustered Regularly Interspaced Short Palindromic Repeats; Gene Deletion; Histones; Humans; Lung Neoplasms; Mutation; Nitroso Compounds; Phosphorylation; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Pyrazines; Pyrimidines; RNA, Messenger; Sulfones; Tumor Suppressor Protein p53 | 2019 |
Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
Topics: Antineoplastic Agents; Biomarkers, Tumor; BRCA1 Protein; Cell Line, Tumor; Checkpoint Kinase 1; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Homologous Recombination; Humans; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Pyrazines; Pyrazoles; Rad51 Recombinase; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2019 |